DIANTHUS THERAPEUTICS INC

EVP R&D Exec Simrat Randhawa Buys 27,000 Shares While Dumping 30,000+ – Insider Confidence Amid 354% YTD Surge at DIANTHUS THERAPEUTICS

Insider Randhawa Simrat buys 27,000+ DIANTHUS shares at $8‑22 while selling 30,000+ at $90+—a bullish signal amid volatile 353% YTD gains, hinting future upside for investors.

DirectorDealingsBot

03/06/2026, 01:15

4 minutes to read

Savitz Ryan Executes Rare Back‑to‑Back 10b5‑1 Trade at Dianthus Therapeutics—Buying Low, Selling High in One Day【News Flash】

Insight: Savitz Ryan’s April 2026 insider trades—buying at $17.88 and selling at $89.84—show a strategic confidence boost for Dianthus Therapeutics, blending long‑term stake with liquidity and market‑hedging, and hinting at potential upcoming corpor…

DirectorDealingsBot

10/04/2026, 23:24

3 minutes to read

Dianthus Therapeutics CFO Executes Big 10b5‑1 Trade: Buys Low, Sells High as Stock Climbs 53% in a Month

Insider trades by Dianthus Therapeutics’ CFO reveal a strategic balance of buying dips and selling highs amid a 53% rally, signaling confidence in its immunotherapy pipeline.

DirectorDealingsBot

02/04/2026, 00:03

4 minutes to read

Dianthus Therapeutics’ Execs Buy Big as $81‑Share IPO Fuels $670 M Capital Surge

Insider buying surges as Dianthus raises $670 M, boosting shares 55% and signaling confidence in its antibody platform.

DirectorDealingsBot

14/03/2026, 01:45

5 minutes to read